Aptevo Therapeutics Inc.
APVO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.04 | 0.00 |
| FCF Yield | -113.91% | -315.06% | -388.66% | -91.62% |
| EV / EBITDA | 0.90 | 0.20 | -0.82 | -1.10 |
| Quality | ||||
| ROIC | -35.59% | -58.01% | -219.74% | -68.01% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 1.14 | 1.03 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 5.71% | -7.88% | -14.17% | -10.28% |
| Safety | ||||
| Net Debt / EBITDA | 2.28 | 0.84 | -0.36 | 0.65 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -3,870.00 |